BACKGROUNDS: Admixture is of great relevance to the clinical application of pharmacogenetics and personalized medicine, but unfortunately these studies have been scarce in Puerto Ricans. Besides, allele frequencies for clinically relevant genetic markers in warfarin response (i.e., CYP2C9 and VKORC1) have not yet been fully characterized in this population. Accordingly, this study is aimed at investigating whether a correlation between overall genetic similarity and CYP2C9 and/or VKORC1 genotypes could be established. METHODS: 98 DNA samples from Puerto Ricans were genotyped for major CYP2C9 and VKORC1 polymorphisms and tested on a physiogenomic (PG)-array to infer population structure and admixture pattern. RESULTS: Analysis affirmed that Puerto Ricans are broadly admixed. A genetic distance dendrogram was constructed by clustering those subjects with similar genetic profiles. Individual VKORC1 and CYP2C9 genotypes were visually overlaid atop the three dendrogram sectors. Sector-1, representing Amerindian ancestry, showed higher VKORC1 -1639G>A variant frequency than the rest of the population (p=0.051). Although CYP2C9*3 allele frequencies matched the expected HapMap values, admixture may explain deviations from published findings regarding VKORC1 -1639G>A and CYP2C9*2 allele frequencies in sector-3. CONCLUSIONS: Results suggest that the observed inter-individual variations in ancestral contributions have significant implications for the way each Puerto Rican responds to warfarin therapy. Our findings provide valuable evidence on the importance of controlling for admixture in pharmacogenetic studies of Puerto Rican Hispanics. Copyright 2010 Elsevier B.V. All rights reserved.
BACKGROUNDS: Admixture is of great relevance to the clinical application of pharmacogenetics and personalized medicine, but unfortunately these studies have been scarce in Puerto Ricans. Besides, allele frequencies for clinically relevant genetic markers in warfarin response (i.e., CYP2C9 and VKORC1) have not yet been fully characterized in this population. Accordingly, this study is aimed at investigating whether a correlation between overall genetic similarity and CYP2C9 and/or VKORC1 genotypes could be established. METHODS: 98 DNA samples from Puerto Ricans were genotyped for major CYP2C9 and VKORC1 polymorphisms and tested on a physiogenomic (PG)-array to infer population structure and admixture pattern. RESULTS: Analysis affirmed that Puerto Ricans are broadly admixed. A genetic distance dendrogram was constructed by clustering those subjects with similar genetic profiles. Individual VKORC1 and CYP2C9 genotypes were visually overlaid atop the three dendrogram sectors. Sector-1, representing Amerindian ancestry, showed higher VKORC1 -1639G>A variant frequency than the rest of the population (p=0.051). Although CYP2C9*3 allele frequencies matched the expected HapMap values, admixture may explain deviations from published findings regarding VKORC1 -1639G>A and CYP2C9*2 allele frequencies in sector-3. CONCLUSIONS: Results suggest that the observed inter-individual variations in ancestral contributions have significant implications for the way each Puerto Rican responds to warfarin therapy. Our findings provide valuable evidence on the importance of controlling for admixture in pharmacogenetic studies of Puerto Rican Hispanics. Copyright 2010 Elsevier B.V. All rights reserved.
Authors: Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie Journal: JAMA Date: 2002-04-03 Impact factor: 56.272
Authors: Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg Journal: Nature Date: 2004-02-05 Impact factor: 49.962
Authors: Michael A Hillman; Russell A Wilke; Michael D Caldwell; Richard L Berg; Ingrid Glurich; James K Burmester Journal: Pharmacogenetics Date: 2004-08
Authors: Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó Journal: Pharmacogenomics Date: 2016-09-16 Impact factor: 2.533
Authors: Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore Journal: Semin Thromb Hemost Date: 2012-10-06 Impact factor: 4.180
Authors: Alga S Ramos; Richard L Seip; Giselle Rivera-Miranda; Marcos E Felici-Giovanini; Rafael Garcia-Berdecia; Yirelia Alejandro-Cowan; Mohan Kocherla; Iadelisse Cruz; Juan F Feliu; Carmen L Cadilla; Jessica Y Renta; Krystyna Gorowski; Cunegundo Vergara; Gualberto Ruaño; Jorge Duconge Journal: Pharmacogenomics Date: 2012-12 Impact factor: 2.533
Authors: Isa I Valentín; Giselle Rivera; Mariely Nieves-Plaza; Iadelisse Cruz; Jessica Y Renta; Carmen L Cadilla; Juan F Feliu; Richard L Seip; Gualberto Ruaño; Jorge Duconge Journal: P R Health Sci J Date: 2014-09 Impact factor: 0.705
Authors: Jorge Duconge; Alga S Ramos; Karla Claudio-Campos; Giselle Rivera-Miranda; Luis Bermúdez-Bosch; Jessicca Y Renta; Carmen L Cadilla; Iadelisse Cruz; Juan F Feliu; Cunegundo Vergara; Gualberto Ruaño Journal: PLoS One Date: 2016-01-08 Impact factor: 3.240